Author

T. F. Westbrook

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

A. Arnal-Estape· 1 shared A. Balabaki· 1 shared C. Hamor· 1 shared C. M. Perou· 1 shared C. Montemayor-Garcia· 1 shared D. Acosta· 1 shared D. Nguyen· 1 shared E. B. Kabotyanski· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Arnal-Estape

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintMar 30, 2022

WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation

Q. Yan, J. F.-Y. Chen, W. Cai…·D. Nguyen

This study identifies WDR5 as an epigenetic regulator that promotes breast cancer growth and metastasis through KMT2-independent translation regulation, suggesting therapeutic strategies targeting WDR5.

DOI 10.1101/2022.03.30.486357

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivJun 16, 2021

Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics

Y. Gao, E. B. Kabotyanski, E. Villegas…·J. M. Rosen

This study shows PLK2 loss predicts better response to PLK1 inhibitors in triple-negative breast cancer and suggests PLK2 as a biomarker for treatment response.

DOI 10.1158/2767-9764.crc-21-0106

mouseexperimental assay

𝕏 PostBluesky